BRIEF — Galderma Nemolizumab Phase II Data Show Relief For Children Moderate — To — Severe Atopic Dermatitis

Oct 15 (Reuters) — GALDERMA GROUP AG: Nemolizumab Phase Ii Data Show Long-term Symptom Relief For Children Aged 2 To 11 Years With Moderate-to-severe Atopic Dermatitis Source text:... Further company coverage: GALD.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;)